CytomX Therapeutics, Inc. (CTMX) |
|
1.785 -0.015 (-0.83%)
|
03-22 11:31 |
|
Open: |
1.84 |
Pre. Close: |
1.8 |
|
High:
|
1.84 |
Low:
|
1.775 |
|
Volume:
|
207,136 |
Market Cap:
|
118(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:15:15 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.53  One year: 2.82 |
| Support: |
Support1: 1.76 Support2: 1.46 |
| Resistance: |
Resistance1: 2.16 Resistance2: 2.41 |
| Pivot: |
1.98 |
| Moving Average: |
MA(5): 1.84 MA(20): 2.03
MA(100): 1.96  MA(250): 1.8 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 7.3 %D(3): 12.5 |
| RSI: |
RSI(14): 33.1 |
| 52-week: |
High: 3.01 Low: 1.16 |
| Average Vol(K): |
3-Month: 2,630 (K) 10-Days: 1,206 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CTMX ] has closed above bottom band by 11.0%. Bollinger Bands are 18.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.87 - 1.89 |
1.89 - 1.9 |
|
Low:
|
1.73 - 1.75 |
1.75 - 1.76 |
|
Close:
|
1.77 - 1.81 |
1.81 - 1.83 |
|
Company Description |
|
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. |
Headline News |
Wed, 22 Mar 2023
Toroso Investments LLC Raises Holdings in CytomX Therapeutics ... - MarketBeat
Tue, 21 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com
Mon, 20 Mar 2023
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus ... - MarketBeat
Sun, 19 Mar 2023
Why I Think Ms. Marvel Is The Most Empowering New Addition In ... - Yahoo Entertainment
Tue, 14 Mar 2023
Breast Cancer Treatment Options Evolved Over the Last 12 Months, Bringing More Hope for 2023 - Baystreet.ca
Fri, 10 Mar 2023
Should You Buy CytomX Therapeutics Inc (CTMX) Stock on Friday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
66 (M) |
| Shares Float |
55 (M) |
|
% Held by Insiders
|
1.3 (%) |
|
% Held by Institutions
|
57.9 (%) |
|
Shares Short
|
1,270 (K) |
|
Shares Short P.Month
|
1,600 (K) |
Stock Financials |
|
EPS
|
-1.31 |
|
EPS Est Next Qtl
|
-0.41 |
|
EPS Est This Year
|
-1.5 |
|
EPS Est Next Year
|
-1.41 |
|
Book Value (p.s.)
|
0.43 |
|
Profit Margin (%)
|
-135.7 |
|
Operating Margin (%)
|
-127.5 |
|
Return on Assets (ttm)
|
-19.2 |
|
Return on Equity (ttm)
|
-139.3 |
|
Qtrly Rev. Growth
|
-3.8 |
|
Gross Profit (p.s.)
|
1.05 |
|
Sales Per Share
|
1.08 |
|
EBITDA (p.s.)
|
-1.35 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-141 (M) |
|
Levered Free Cash Flow
|
-46 (M) |
Stock Valuations |
|
PE Ratio
|
-1.36 |
|
PEG Ratio
|
1.6 |
|
Price to Book value
|
4.13 |
|
Price to Sales
|
1.63 |
|
Price to Cash Flow
|
-0.84 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
